| 1. |
- Basabe-Desmonts, L., et al.
(författare)
-
Disposable bioanalytical microdevice for monitoring the effect of anti-platelet drugs
- 2010
-
Ingår i: 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010. - : CBMS. - 9781618390622 ; , s. 1388-1390
-
Konferensbidrag (refereegranskat)abstract
- We report a disposable self-powered integrated microfluidic chip that enables a rapid and simple platelet-function assay from small samples of whole blood. The chip integrates a single-cell adhesion assay with a microfluidic platform; it enables accurate quantification of platelet adhesion, and it controls whole blood flow rate, shear stress, volume of sample, and assay time.
|
|
| 2. |
|
|
| 3. |
- Delage, F., et al.
(författare)
-
ADS fuel developments in Europe : Results from the EUROTRANS integrated project
- 2011
-
Ingår i: Energy Procedia. - : Elsevier BV. ; , s. 303-313
-
Konferensbidrag (refereegranskat)abstract
- Fuels to be used in Accelerator Driven Systems dedicated to Minor Actinides transmutation can be described as highly innovative in comparison with those used in critical cores. Indeed, ADS fuels are not fertile, so as to improve the transmutation performance and they contain high volumetric concentrations (∼50%) of minor actinides and plutonium compounds. This unusual fuel composition results in high gamma and neutron emissions during its fabrication, as well as degraded performances under irradiation. Ceramic-Ceramic and Ceramic Metallic composite fuels consisting of particles of (Pu, MA)O2 phases dispersed in a magnesia or molybdenum matrix were investigated within the European Research programme for Transmutation, as driver fuels for a prospective 400MWth transmuter: the European Facility for Industrial Transmutation. Fuel performances and safety of preliminary core designs were evaluated to support the project. Out -of-pile as well as in-pile experiments were carried out to gain essential knowledge on properties and behaviour under irradiation of these types of fuel. This paper gives an overview of experimental results within the project.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Webb, Ryan, et al.
(författare)
-
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients
- 2011
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 70:1, s. 151-156
-
Tidskriftsartikel (refereegranskat)abstract
- Background Systemic lupus erythematosus (SLE) is a chronic, multiorgan, autoimmune disease that affects people of all ages and ethnicities. Objectives To explore the relationship between age at disease onset and many of the diverse manifestations of SLE. Additionally, to determine the relationship between age of disease onset and genetic risk in patients with SLE. Methods The relationship between the age at disease onset and SLE manifestations were explored in a multiracial cohort of 1317 patients. Patients with SLE were genotyped across 19 confirmed genetic susceptibility loci for SLE. Logistic regression was used to determine the relationships between the number of risk alleles present and age of disease onset. Results Childhood-onset SLE had higher odds of proteinuria, malar rash, anti-dsDNA antibody, haemolytic anaemia, arthritis and leucopenia (OR=3.03, 2.13, 2.08, 2.50, 1.89, 1.53, respectively; p values < 0.0001, 0.0004, 0.0005, 0.0024, 0.0114, 0.045, respectively). In female subjects, the odds of having cellular casts were 2.18 times higher in childhood-onset than in adult-onset SLE (p=0.0027). With age of onset >= 50, the odds of having proteinuria, cellular casts, anti-nRNP antibody, anti-Sm antibody, anti-dsDNA antibody and seizures were reduced. However, late adult-onset patients with SLE have higher odds of developing photosensitivity than early adult-onset patients. Each SLE-susceptibility risk allele carried within the genome of patients with SLE increased the odds of having a childhood-onset disease in a race-specifi c manner: by an average of 48% in Gullah and 25% in African-Americans, but this was not significant in Hispanic and European-American lupus patients. Conclusions The genetic contribution towards predicting early-onset disease in patients with SLE is quantified for the first time. A more severe SLE phenotype is found in patients with early-onset disease in a large multi-racial cohort, independent of gender, race and disease duration.
|
|
